MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from sale of shares und...
Prepaid assets and other current...
Interest accrued on license paya...
Negative Cash Flow Breakdown
Net loss
Accrued compensation
Other accrued expenses
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-4,866,635
-5,625,749
-4,553,953
-5,407,470
Stock-based compensation expense
1,340,769
1,356,389
1,541,675
1,800,614
Change in estimated fair value of warrant liability
-
-
0
0
Gain on settlement of warrant liability
-
-
0
0
Loss on issuance of related party convertible notes payable at fair value
-
-
0
0
Change in estimated fair value of related party convertible notes payable
-
-
0
0
Issuance of restricted shares in exchange for services
0
138,500
-
-
Interest accrued on license payable
5,063
5,062
5,062
15,188
Prepaid assets and other current assets
-63,344
-98,552
-35,241
323,334
Other assets
0
0
0
0
Accounts payable
-150,602
-322,797
185,555
-1,828,207
Accrued compensation
-499,072
297,509
-257,979
-541,835
Accrued interest
-
-
0
-81,082
Other accrued expenses
-297,990
-964,793
-691,644
-311,583
Net cash used in operating activities
-4,405,123
-5,017,327
-3,736,043
-6,677,709
Proceeds from sale of shares under at-the-market facility, net
731,589
519,624
0
1,663,236
Proceeds from initial public offering, net of underwriting discounts and commissions
-
-
0
0
Payment of offering costs related to initial public offering
-
-
0
0
Proceeds from issuances of related party convertible notes payable
-
-
0
0
Proceeds from issuance of shares of common stock under underwritten public offering, net of underwriting discounts and offering costs
-
-
0
15,573,966
Payment of taxes from withholding of common stock on settlement of restricted stock units
0
527,716
-
-
Proceeds from issuance of related party short-term loan
-
-
0
0
Proceeds from issuance of shares of common stock under june 2025 private placement, net of issuance costs of 43,933
0
-
0
-29,084
Payment of related party short-term loan
-
-
0
0
Proceeds from issuance of shares of common stock under the committed equity facility, net of issuance costs of 343,848
0
-
-
-
Proceeds from the exercise of stock options
0
-
0
0
Deferred offering costs
34,629
0
29,297
273,528
Net cash provided by financing activities
696,960
-8,092
-29,297
17,109,816
Net change in cash and cash equivalents
-3,708,163
-5,025,419
-3,765,340
10,432,107
Cash and cash equivalents, beginning of period
8,134,004
13,159,423
16,924,763
8,641,622
Cash and cash equivalents, end of period
4,425,841
8,134,004
13,159,423
16,924,763
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sale of
shares under...
$731,589
(-66.18%↓ Y/Y)
Net cash provided by
financing activities
$696,960
(-89.51%↓ Y/Y)
Canceled cashflow
$34,629
Net change in cash
and cash...
-$3,708,163
(-72.56%↓ Y/Y)
Canceled cashflow
$696,960
Stock-based compensation
expense
$1,340,769
(-50.42%↓ Y/Y)
Prepaid assets and other
current assets
-$63,344
(82.90%↑ Y/Y)
Interest accrued on
license payable
$5,063
(-50.00%↓ Y/Y)
Deferred offering costs
$34,629
(-80.24%↓ Y/Y)
Net cash used in
operating activities
-$4,405,123
(49.90%↑ Y/Y)
Canceled cashflow
$1,409,176
Net loss
-$4,866,635
(60.33%↑ Y/Y)
Accrued compensation
-$499,072
(-199.88%↓ Y/Y)
Other accrued
expenses
-$297,990
(77.95%↑ Y/Y)
Accounts payable
-$150,602
(-113.33%↓ Y/Y)
Buy us a coffee
ACTUATE THERAPEUTICS, INC. (ACTU)
ACTUATE THERAPEUTICS, INC. (ACTU)